Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.
Semaglutide and tirzepatide appear to have similar cardiovascular outcomes in patients with obesity and ASCVD, according to this study.
Where it sits
this study against the rest of the tirzepatide corpusSummary and findings
This study compared cardiovascular outcomes between semaglutide and tirzepatide in adults with obesity and atherosclerotic cardiovascular disease. A total of 5665 patients were analyzed per group, with no statistically significant differences in major adverse cardiovascular events. The findings suggest similar cardiovascular outcomes for both treatments.
Abstract
<h4>Background</h4>Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited.<h4>Methods</h4>This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m<sup>2</sup> and ASCVD initiating treatment with semaglutide or tirzepatide. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to analyze 3-point major adverse cardiovascular events (MACE: all-cause mortality, myocardial infarction, or ischemic stroke) and 5-point MACE (3-point MACE plus heart failure exacerbation and revascularization).<h4>Results</h4>After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide in 5-point MACE (19.5% vs 17.1%; HR 1.03; 95% CI 0.94-1.12), 3-point MACE (17.4% vs 15.4%; HR 1.04; 95% CI 0.95-1.14), or any individual component.<h4>Conclusions</h4>Semaglutide and tirzepatide were associated with similar cardiovascular outcomes. Prospective head-to-head trials are warranted to validate these results.
Background
This paper addresses the comparative cardiovascular outcomes of glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in patients with atherosclerotic cardiovascular disease (ASCVD) without diabetes. Previous studies have shown varying cardiovascular effects of GLP-1 agonists, but data comparing these specific agents in this population are limited. Understanding these outcomes is crucial for guiding treatment decisions in patients with obesity and ASCVD.
Methods
The study employed a propensity score-matched retrospective design, focusing on adults aged ≥45 years with a body mass index ≥27 kg/m² and ASCVD. A total of 5665 patients initiating treatment with either semaglutide or tirzepatide were analyzed. The primary outcome measures included 3-point major adverse cardiovascular events (MACE) and 5-point MACE, which included additional components such as heart failure exacerbation and revascularization.
Results
The primary endpoint for 5-point MACE showed no statistically significant difference between semaglutide and tirzepatide, with rates of 19.5% and 17.1%, respectively (HR 1.03; 95% CI 0.94-1.12). Similarly, for 3-point MACE, the rates were 17.4% for semaglutide and 15.4% for tirzepatide (HR 1.04; 95% CI 0.95-1.14). No significant differences were observed for any individual component of the outcomes measured.
Interpretation
The findings suggest that semaglutide and tirzepatide are associated with similar cardiovascular outcomes in this specific patient population. While the hazard ratios indicate no significant differences, the effect sizes are small, which raises questions about clinical relevance. The retrospective nature of the study and reliance on propensity score matching introduce potential confounding factors that limit the conclusions that can be drawn. Further prospective head-to-head trials are warranted to validate these results and clarify the implications for clinical practice.
Key findings
- 5-point MACE: 19.5% semaglutide vs 17.1% tirzepatide; HR 1.03; 95% CI 0.94-1.12.
- 3-point MACE: 17.4% semaglutide vs 15.4% tirzepatide; HR 1.04; 95% CI 0.95-1.14.
- 5665 patients analyzed per group.
Limitations
- retrospective design may introduce bias
- propensity score matching may not account for all confounders
- small effect sizes raise questions about clinical relevance
- no individual component showed significant differences
- further prospective trials needed to validate results